This apparent discrepancy might be a consequence of the relative specificity of SNAP25 for Alzheimer’s disease while Alzheimer’s disease pathology was largely absent in the current cohort (only 8% of participants that underwent amyloid PET demonstrated positivity). This evidence concerns the gene SNAP25 and Alzheimer disease.